NSAC releases statement on UFC 235 Jon Jones drug screening; ‘Adverse Analytical Finding’ addressed

- Advertisement -

The drug test findings leading up to Jones’ UFC 235 contest against Anthony ‘Lionheart’ Smith, have arrived. Following his bust in July of 2017 after his win over Daniel Cormier, Jones entered a suspension from the UFC for a 15-month long period. Since his comeback last December, Jones has been subject to a series of drug screening procedures, in turn fulfilling his post and pre-fight doping obligations.

Picture Courtesy: The Independent

On February 28th, this past Thursday, The Nevada State Athletic Commission shared five separate drug test results performed on Jones, to the public. According to the statement, Jones tested positive for an M3 Metabolite of oral-turinabol – a substance that has been lingering in his system since his positive drug results in July 2017. However, on three other occasions, Jones was found to be clear of the substance and according to president and director of the Sports Medicine and Research Laboratory, Dr. Daniel Eichner, is devoid of taking home any advantage over Anthony Smith, this coming Saturday night.

In January 2019, Jones was granted with a single-fight license by the NSAC, allowing him to compete in UFC’s March 2nd card at the T-Mobile Arena in Las Vegas. In the NAC’s closing statement on the matter, it read:

“The above analytical findings are consistent with the NSAC’s January 29, 2019 order to issue Mr. Jones a single fight license and, as such, the findings will not preclude him from competing on March 2, 2019. Mr. Jones will continue to be subject to random drug testing and monitoring so as to assure his continued compliance.”


If any content is used from this article, kindly backlink to this page.

If you like reading about sports, make sure you check out SportsIndiaShow.com
Also follow India’s biggest arm wrestling tournament at ProPanja.com

- Advertisement -

Related articles

Exit mobile version